Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Library CD
Volume 22, 2018 Archive
Six back issues from 2018 on one convenient archive.
Permanent storage and easy retrieval of IJPC articles and formulations.
  • Print journal articles in color from the PDF file for your marketing needs.
  • Eliminate long searches through past issues for formulations, compatibility studies, standard operating procedures, marketing ideas, and literature reviews.

Only $200.00


(Select Format)
Mailed CD
Instant PDF Download

This archive contains the following articles listed by volume, issue and page number:

Issues Included
Volume/Issue Date Title
Vol. 22 No. 1 January/February 2018 Volume 22, Number 1
Vol. 22 No. 2 March/April 2018 Volume 22, Number 2
Vol. 22 No. 3 May/June 2018 Volume 22, Number 3
Vol. 22 No. 4 July/August 2018 Volume 22, Number 4
Vol. 22 No. 5 September/October 2018 Volume 22, Number 5
Vol. 22 No. 6 November/December 2018 Volume 22, Number 6

Volume 22, 2018 Articles

Volume 22, 2018 Articles
Title (Click for Details) Vol/Issue Page
PreScription: 2017--Some Good Things Happened and Some Others Vol. 22 No. 1 4
Certification, Accreditation, and Credentialing for 503A Compounding Pharmacies Vol. 22 No. 1 7
Pain: Systematic Review of Pharmacy Compounding of Pain Medication Vol. 22 No. 1 19
The International Academy of Compounding Pharmacists: Government Affairs Lookback on 2017 Accomplishments and Look Ahead at 2018 Initiatives Vol. 22 No. 1 26
Basics of Compounding: Providing Pharmacy Services to Bariatric Surgery Patients Vol. 22 No. 1 30
Sterile Basics of Compounding: Relationship Between Syringe Size and Dosing Accuracy Vol. 22 No. 1 41
Calculations Vol. 22 No. 1 48
Glutamate and Aspartate Cardioplegia Additive Solution Vol. 22 No. 1 50
Mercaptopurine 50 mg/mL in Ora-Sweet and Ora-Plus Suspension Vol. 22 No. 1 51
Metronidazole 50 mg/mL in Ora-Blend Suspension Vol. 22 No. 1 52
Miconazole 10% in Recura Topical Cream Vol. 22 No. 1 53
Naproxen 25 mg/mL in Oral Mix or Oral Mix SF Vol. 22 No. 1 54
Penicillamine-D 50 mg/mL in SyrSpend SF pH4 Oral Suspension Vol. 22 No. 1 55
Ranitidine 15 mg/mL in SyrSpend SF pH4 Vol. 22 No. 1 56
Sodium Citrate 9% Nasal Spray for Olfactory Disorders Vol. 22 No. 1 57
Thalidomide 20 mg/mL in Ora-Plus and Ora-Sweet Suspension Vol. 22 No. 1 58
Voriconazole 40-mg/mL Oral Suspension Vol. 22 No. 1 59
Effects of Compounded Stanford Modified Oral Rinse (MucoLox) on the Survival and Migration of Oral Keratinocytes and Fibroblasts: Implications for Wound Healing Vol. 22 No. 1 60
Stability of an Alcohol-free, Dye-free Hydrocortisone (2 mg/mL) Compounded Oral Suspension Vol. 22 No. 1 66
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection Vol. 22 No. 1 76
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride Vol. 22 No. 1 86
PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing Vol. 22 No. 2 92
Pharmacogenomics: Precision Pharmacy in 503A Compounding Vol. 22 No. 2 95
Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management Vol. 22 No. 2 108
IACP Legislative/Regulatory Update: The International Academy of Compounding Pharmacists Testifies at U.S. House of Representatives' Energy & Commerce Health Subcommittee Pharmacy Compounding Hearing Vol. 22 No. 2 125
Quality Control: Lessons Learned from a Trimix Stability Study in a 503A Compounding Pharmacy Vol. 22 No. 2 129
Basics of Compounding: Compounding Microemulsions Vol. 22 No. 2 137
Calculations Vol. 22 No. 2 144
Clonidine Hydrochloride 10 mg/mL in Inorpha Solution Vol. 22 No. 2 146
Dorzolamide 2% and Timolol 0.5% Ophthalmic Solution Vol. 22 No. 2 147
Lamotrigine 1-mg/mL in SyrSpend SF pH4 Oral Suspension Vol. 22 No. 2 148
Levodopa and Carbidopa Rectal Suspension Vol. 22 No. 2 149
Prochlorperazine Edisylate 0.5% Nasal Spray Vol. 22 No. 2 150
Rolapitant Injectable Emulsion with Palonosetron Hydrochloride Admixture Vol. 22 No. 2 151
Spironolactone 5-mg/mL in Suspendit Oral Suspension Vol. 22 No. 2 152
Trilostane 5-mg/mL in Cod Liver Oil Suspension (Vet) Vol. 22 No. 2 153
Evaluation and Comparison of Wound Healing Properties of an Ointment (AlpaWash) Containing Brazilian Micronized Propolis and Peucedanum ostruthium Leaf Extract in Skin Ulcer in Rats Vol. 22 No. 2 154
The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions Vol. 22 No. 2 164
Topical Ketamine in the Treatment of Complex Regional Pain Syndrome Vol. 22 No. 2 172
PreScription: Influence and Sphere of Influence Vol. 22 No. 3 180
Pitch Ointment: Applications in Scar and Wound Management Vol. 22 No. 3 182
Establishing a Rationale for Compounding Hormone Replacement Therapy Vol. 22 No. 3 190
Case Report of a Human Papillomavirus Infection Treated with Green Tea Extract and Curcumin Vaginal Compounded Medications Vol. 22 No. 3 196
Your Presence is Needed at Compounders on Capitol Hill! Vol. 22 No. 3 204
Quality Control–Sterile Compounding: Analytical Methods. Density Determinations and Quality Control in Nonsterile and Sterile Compounding Vol. 22 No. 3 206
Basics of Compounding–Nonsterile: Compounding Self-emulsifying Drug Delivery Systems and Other Self-emulsifying Lipid Formulations, Part 1 Vol. 22 No. 3 220
Calculations Vol. 22 No. 3 230
Anhydrous Silicon Base Topical Gel Vehicle Vol. 22 No. 3 232
Atenolol 1 mg/mL or 5 mg/mL in SyrSpend SF pH4 Vol. 22 No. 3 233
Dorzolamide 2% Ophthalmic Solution Vol. 22 No. 3 234
Gabapentin 100 mg/mL in Oral Mix or Oral Mix SF Suspension Vol. 22 No. 3 235
Pyrimethamine 2 mg/mL in Ora-Plus and Ora-Sweet Oral Suspension Vol. 22 No. 3 236
Rolapitant Injectable Emulsion with Dexamethasone Sodium Phosphate Admixture Vol. 22 No. 3 237
Simvastatin 1 mg/mL in SyrSpend SF pH4 Oral Suspension Vol. 22 No. 3 238
Trimethoprim 20 mg/mL and Sulfadiazine 100 mg/mL in Suspendit Oral Suspension Vol. 22 No. 3 239
Investigation of the Physical, Chemical, and Microbiological Stability of Oral Solutions Compounded with Herbals Vol. 22 No. 3 240
Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations Vol. 22 No. 3 247
The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia Vol. 22 No. 3 252
Trace Level Analysis of Airborne Hormone Particulates Vol. 22 No. 3 257
Erratum: Formulation: Lansoprazole 3-mg/mL Oral Suspension Vol. 22 No. 3 263
PreScription: Factors Related to Drug Waste and Pharmacy Solutions Vol. 22 No. 4 268
Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report Vol. 22 No. 4 270
Compounding from a Pharmacy Student's Perspective Vol. 22 No. 4 281
The History, Symptoms, Causes, Risk Factors, Types, Diagnosis, Treatments, and Prevention of Gout, Part 1 Vol. 22 No. 4 284
Quality Control: Water Activity Considerations for Beyond-use Dates Vol. 22 No. 4 288
Basics of Compounding--Nonsterile: Compounding Self-emulsifying Drug Delivery Systems and Other Self-emulsifying Lipid Formulations, Part 2 Vol. 22 No. 4 294
Basics of Sterile Compounding: Criteria for Determining Beyond-use Dating Vol. 22 No. 4 303
Calculations Vol. 22 No. 4 314
Anhydrous Medium-chain Triglycerides Gel Vol. 22 No. 4 316
Budesonide 1-mg//10-mL Mucolox Oral Suspensions Vol. 22 No. 4 317
Cinacalcet 5-mg/mL in Oral-Plus/Ora-Sweet Suspension Vol. 22 No. 4 318
Ketoprofen 10% in Pluronic Lecithin Organogel Vol. 22 No. 4 319
Metronidazole Benzoate 70 mg/mL in SyrSpend SF Oral Suspension Vol. 22 No. 4 320
Midazolam 1 mg/mL in SyrSpend SF or SyrSpend SF Cherry Vol. 22 No. 4 321
Minoxidil 50 mg/mL in Espumil Foam Base Vol. 22 No. 4 322
Oseltamivir Phosphate 15 mg/mL in SyrSpend SF Vol. 22 No. 4 323
Pentoxifylline 5% in Dermabase Vol. 22 No. 4 324
Propranolol Hydrochloride 1 mg/mL in SyrSpend SF Oral Suspension Vol. 22 No. 4 325
Stability of Extemporaneously Prepared Sodium Benzoate Oral Suspension Vol. 22 No. 4 326
Kinetics of Tetracaine Solvolysis in Propylene Glycol Vol. 22 No. 4 329
Long-term Physicochemical Stability of Concentrated Solutions of Noradrenaline Bitartrate in Polypropylene Syringes for Administration in the Intensive Care Unit Vol. 22 No. 4 335
Comparative Stability of Vitamin K1 Oral Liquids Prepared in Sterile Water for Injection and Stored in Amber Glass Bottles and Amber Plastic Syringes Vol. 22 No. 4 340
Antineoplastic Drug Contamination on the Outside of Prepared Infusion Bags Vol. 22 No. 4 345
PreScription: Updating Formulations Vol. 22 No. 5 356
Current Trends and Emerging Priorities in Compounded Preparations for Children Vol. 22 No. 5 358
Certification of Powder-containment Hoods for Nonsterile Compounding Vol. 22 No. 5 369
Compounding Enclosures: Ensuring Safety During the Preparation of Sterile and Nonsterile Formulations Vol. 22 No. 5 387
Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 1 Vol. 22 No. 5 401
Calculations Vol. 22 No. 5 406
Cysteamine 0.5% Ophthalmic Solution Vol. 22 No. 5 408
Fluoxetine 50 mg/mL in Pluronic Lecithin Organogel Vol. 22 No. 5 409
Pergolide Mesylate 0.2-mg/mL Oral Liquid, Veterinary Vol. 22 No. 5 410
Torsemide 5 mg/mL in Ora-Plus:Ora-Sweet Suspension Vol. 22 No. 5 411
Stability of Tranexamic Acid Mouth Rinse Vol. 22 No. 5 412
Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Vol. 22 No. 5 417
A Cold Process Preparation of Vetiveria zizanioides (L.) Nash Oil Lotions using Simulgel FL as an Emulsifier Vol. 22 No. 5 424
Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding Vol. 22 No. 5 433
PreScription: Standardized Concentrations: Pro or Con? Vol. 22 No. 6 444
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications Vol. 22 No. 6 446
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Vol. 22 No. 6 456
Case Study: Absorption of Testosterone Cream via Scrotal Delivery Vol. 22 No. 6 466
Compounding from a Pharmacy Student's Perspective: Staying Competitive as a Compounding Pharmacy Vol. 22 No. 6 471
Basics of Sterile Compounding. Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 2 Vol. 22 No. 6 475
Basics of Compounding: Vehicles for Compounded Oral Liquid Medications: A Review Vol. 22 No. 6 480
Calculations Vol. 22 No. 6 490
Clonazepam 0.2 mg/mL in SyrSpend SF pH4 Oral Suspension Vol. 22 No. 6 492
Diltiazem Hydrochloride 12 mg/mL in SyrSpend SF pH4 Oral Suspension Vol. 22 No. 6 493
Enalapril Maleate 1 mg/mL in SyrSpend SF pH4 Oral Suspension Vol. 22 No. 6 494
Hydrocortisone 2 mg/mL in Inorpha Suspension Vol. 22 No. 6 495
Hydroxyurea 100 mg/mL in Ora-Plus:Ora-Sweet, Ora-Plus: Ora-Sweet SF, Ora-Blend or Oral-Blend SF Oral Suspensions Vol. 22 No. 6 496
Prednisone 5 mg/mL ir Oral Mix Suspension Vol. 22 No. 6 497
Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin Vol. 22 No. 6 498
Physical and Chemical Stability of Estriol 0.025% to 1% Vaginal Creams (VersaBase) Vol. 22 No. 6 504
Compounded Orodispersible Films with Natural Ingredients for Halitosis: A Clinical Experience Vol. 22 No. 6 512
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4 Vol. 22 No. 6 516
Errata Vol. 22 No. 6 527